DGX - Quest Diagnostics Incorporated
NEXT EARNINGS:
Apr 28, 2026
EPS Est: $2.38
|
Rev Est: $2.8B
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$215.10
DETAILS
HIGH:
$235.00
LOW:
$200.00
MEDIAN:
$214.50
CONSENSUS:
$215.10
UPSIDE:
2.65%
Market Cap:
23.31B
Volume:
661,818
Avg Volume:
1,052,171
52 Week Range:
157.2-213.2
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
0.68
Last Dividend:
$3.20
Exchange:
NYSE
Country:
US
Employees:
55,000
IPO Date:
1996-12-17
EPS (TTM):
8.87
P/E Ratio:
19.42
Revenue (TTM):
11.04B
Total Assets:
16.23B
Total Debt:
6.92B
Cash & Equiv:
420.00M
Rev Growth (5Y):
3.2%
EPS Growth (5Y):
-3.6%
FCF Growth (5Y):
-3.1%
ROCE:
11.3%
Debt/Equity:
0.96
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $2.42 | $2.35 | +3.0% | $2.8B | $2.8B | +0.8% |
| 2025-10-21 | $2.60 | $2.50 | +4.0% | $2.8B | $2.7B | +2.9% |
| 2025-07-22 | $2.62 | $2.57 | +1.9% | $2.8B | $2.7B | +1.3% |
| 2025-04-22 | $2.21 | $2.15 | +2.8% | $2.7B | $2.6B | +0.8% |
| 2025-01-30 | $2.23 | $2.19 | +1.8% | $2.6B | $2.6B | +1.6% |
| 2024-10-22 | $2.30 | $2.26 | +1.8% | $2.5B | $2.4B | +2.3% |
| 2024-07-23 | $2.35 | $2.34 | +0.4% | $2.4B | $2.4B | +0.3% |
| 2024-04-23 | $2.04 | $1.86 | +9.7% | $2.4B | $2.3B | +3.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.04B | 9.87B | 9.25B | 9.88B | 10.79B | 9.44B | 7.73B | 7.53B | 7.71B | 7.51B | 7.49B | 7.43B |
| Net Income | 992.00M | 871.00M | 854.00M | 946.00M | 2.00B | 1.43B | 858.00M | 736.00M | 772.00M | 645.00M | 709.00M | 556.00M |
| EPS | 8.87 | 7.80 | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.41 | 5.63 | 4.58 | 4.92 | 3.83 |
| Total Assets | 16.23B | 16.15B | 14.02B | 12.84B | 13.61B | 14.03B | 12.84B | 11.00B | 10.50B | 10.10B | 9.96B | 9.88B |
| Total Debt | 6.92B | 7.09B | 5.50B | 4.71B | 4.77B | 4.81B | 5.42B | 3.99B | 3.85B | 3.73B | 3.65B | 3.76B |
| Cash & Equivalents | 420.00M | 549.00M | 686.00M | 315.00M | 872.00M | 1.16B | 1.19B | 135.00M | 137.00M | 359.00M | 133.00M | 192.00M |
| Operating Cash Flow | 1.89B | 1.33B | 1.27B | 1.72B | 2.23B | 2.00B | 1.24B | 1.20B | 1.18B | 1.07B | 810.00M | 938.00M |
| Free Cash Flow | 1.36B | 909.00M | 864.00M | 1.31B | 1.83B | 1.59B | 843.00M | 817.00M | 923.00M | 776.00M | 547.00M | 630.00M |
| FCF per Share | 12.24 | 8.19 | 7.71 | 11.33 | 14.64 | 11.84 | 6.29 | 6.01 | 6.74 | 5.54 | 3.80 | 4.34 |
| Book Value | 7.17B | 6.78B | 6.31B | 5.89B | 6.44B | 6.76B | 5.64B | 5.22B | 4.92B | 4.63B | 4.68B | 4.30B |
| Cash & ST Investments | 420.00M | 549.00M | 686.00M | 315.00M | 872.00M | 1.16B | 1.19B | 135.00M | 137.00M | 359.00M | 133.00M | 192.00M |
| ROC Equity | 0.14 | 0.13 | 0.14 | 0.16 | 0.31 | 0.21 | 0.15 | 0.14 | 0.16 | 0.14 | 0.15 | 0.13 |